AI Article Synopsis

  • The study aimed to evaluate the effectiveness and side effects of nebulized ketamine in emergency patients with pain, comparing three different doses: 0.75 mg/kg, 1 mg/kg, and 1.5 mg/kg.
  • In a randomized, double-blind trial involving 120 adults, researchers measured pain relief at 30 minutes using a numeric scale and tracked the need for additional pain relief and adverse events.
  • Results showed no significant differences in pain relief among the three doses, with no serious side effects or vital sign changes noted, indicating that all doses were similarly effective for short-term pain management.

Article Abstract

Study Objective: We aimed to assess and compare the analgesic efficacies and adverse effects of ketamine administered through a breath-actuated nebulizer at 3 different dosing regimens for emergency department patients presenting with acute and chronic painful conditions.

Methods: This was a prospective, randomized, double-blinded trial comparing 3 doses of nebulized ketamine (0.75 mg/kg, 1 mg/kg, and 1.5 mg/kg) administered through breath-actuated nebulizer in adult emergency department patients aged 18 years and older with moderate to severe acute and chronic pain. The primary outcome included the difference in pain scores on an 11-point numeric rating scale between all 3 groups at 30 minutes. Secondary outcomes included the need for rescue analgesia (additional doses of nebulized ketamine or intravenous morphine) and adverse events in each group at 30 and 60 minutes.

Results: We enrolled 120 subjects (40 per group). The difference in mean pain scores at 30 minutes between the 0.75 mg/kg and 1 mg/kg groups was 0.25 (95% confidence interval [CI] 1.28 to 1.78); between the 1 mg/kg and 1.5 mg/kg groups was -0.225 (95% CI -1.76 to 1.31); and between the 0.75 mg/kg and 1.5 mg/kg groups was 0.025 (95% CI -1.51 to 1.56). No clinically concerning changes in vital signs occurred. No serious adverse events occurred in any of the groups.

Conclusion: We found no difference between all 3 doses of ketamine administered through breath-actuated nebulizer for short-term treatment of moderate to severe pain in the emergency department.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annemergmed.2021.04.031DOI Listing

Publication Analysis

Top Keywords

mg/kg mg/kg
20
emergency department
16
nebulized ketamine
12
administered breath-actuated
12
breath-actuated nebulizer
12
075 mg/kg
12
mg/kg groups
12
mg/kg
9
dosing regimens
8
prospective randomized
8

Similar Publications

In a series of studies on blood-brain barrier transportable peptides, a soybean dipeptide, Tyr-Pro, penetrated the mouse brain parenchyma after oral intake and improved short and long memory impairment in acute Alzheimer's model mice. Here, we aimed to clarify the anti-dementia effects of this peptide administered to SAMP8 mice prior to dementia onset. At the end of the 25-week protocol in 16-week-old SAMP8 mice, Tyr-Pro (10 mg/kg/day) significantly improved the reduced spatial learning ability compared with that in the control and amino acid (Tyr + Pro) groups as indicated by the results of Morris water maze tests conducted for five consecutive days.

View Article and Find Full Text PDF

The emergence of single-atom catalysts offers exciting prospects for the green production of hydrogen peroxide; however, their optimal local structure and the underlying structure-activity relationships remain unclear. Here we show trace Fe, up to 278 mg/kg and derived from microbial protein, serve as precursors to synthesize a variety of Fe single-atom catalysts containing FeNO (1 ≤ x ≤ 4) moieties through controlled pyrolysis. These moieties resemble the structural features of nonheme Fe-dependent enzymes while being effectively confined on a microbe-derived, electrically conductive carbon support, enabling high-current density electrolysis.

View Article and Find Full Text PDF

Background: Subcutaneous emicizumab, a factor VIII (FVIII)-mimicking bispecific monoclonal antibody, can effectively prevent bleeds in haemophilia A (HA) patients with/without inhibitors; however, its standard-dose regimens are financially burdensome. Low-dose emicizumab prophylaxis may alternatively be applied to noninhibitor HA patients in resource-limited settings.

Methods: During 2023, Thai patients with noninhibitor severe HA or moderate HA with severe bleeding phenotype (historical annualized bleeding rate [ABR] >5 bleeds/year before regular FVIII prophylaxis) who received low-/intermediate-dose FVIII secondary prophylaxis ≥8 months were enrolled.

View Article and Find Full Text PDF

Background: Pain management is a critical part of treatment in patients with chest trauma. Opioids and nonsteroidal anti-inflammatory drugs have been the most commonly used medications. However, their side effects have drawn attention to other medications.

View Article and Find Full Text PDF

Objectives: We aimed to investigate the effect of hand therapy (HT) on oxytocin and oxytocin receptor expression in a chemotherapy-induced peripheral neuropathy (CIPN) model mouse.

Methods: CIPN model mouse was induced by intraperitoneal injection of paclitaxel (PTX; 4 mg/kg) on days 0, 2, 4 and 6 of the study. HT was performed on the CIPN mice once daily for 14 consecutive days, starting on day 8 after the PTX injection.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!